Zacks Research Issues Negative Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Zacks Research reduced their Q1 2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Zacks Research analyst R. Department now expects that the company will post earnings of ($1.60) per share for the quarter, down from their prior estimate of ($1.51). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.08) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.60) EPS, FY2025 earnings at ($6.39) EPS, Q1 2026 earnings at ($1.82) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.32) EPS and FY2026 earnings at ($6.16) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a research report on Thursday. Needham & Company LLC reaffirmed a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday. Truist Financial upped their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Bank of America reduced their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Hold" and a consensus price target of $74.05.

CRISPR Therapeutics Stock Performance

CRSP stock traded up $0.19 during mid-day trading on Monday, reaching $43.49. The company had a trading volume of 2,047,808 shares, compared to its average volume of 2,022,014. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.37 and a beta of 1.67. The firm has a fifty day simple moving average of $42.06 and a 200 day simple moving average of $46.25.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company's stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its position in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. Baker BROS. Advisors LP increased its stake in CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after purchasing an additional 743,075 shares during the last quarter. State Street Corp lifted its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after buying an additional 599,304 shares during the period. Norges Bank acquired a new stake in CRISPR Therapeutics in the 4th quarter worth about $17,458,000. Finally, Contrarius Group Holdings Ltd purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $14,516,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.